| Agent | ↓ Exacerbations | ↑ Lung Function | OCS ↓ | Special Feature |
|---|---|---|---|---|
| Omalizumab (IgE) | 25% | ± | — | >6 years of age, IgE |
| Mepolizumab (IL-5) | 50% | + | ++ | Greatest experience of anti-IL5s |
| Reslizumab (IL-5) | 50% | ++ | — | Weight — base dose (IV) |
| Benralizumab (IL-5R) | 50% | ++ | ++ | q 8 wks and IL-5R |
| Dupilumab (IL-4/IL-13) | 50% | ++ | ++ | Eosinophils, FeNO |
| Tezepelumab (anti-TSLA) | 50% | ++ | — | No biomarker necessary |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.